Under the scheme of amalgamation for merger, subsidiaries such as PHL Capital Private Limited, Piramal Pharmaceutical Development Services Private Limited and Oxygen Bio Research Private Limited will merge with Piramal Enterprises Ltd.
"Since all the transferor companies are step down wholly owned subsidiaries of the company, no shares are proposed to be issued pursuant to the merger. This scheme is subject to requisite approvals, including under the Listing Agreement and by the hon’ble High Courts," company said in a statement.
Piramal Pharmaceutical Development Services Private Limited, is R&D arm, working under Piramal Healthcare. Oxygen Bio Research Pvt. Ltd is a contract research organisation (CRO) working on the synthetic drug discovery programme.
Piramal Capital is one of the group's finance arm. On Monday, shares of PEL were closed at Rs 554/1, up by 1.52%.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)